Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
Gan & Lee Pharmaceuticals has initiated GRADUAL-3, a Phase 3 clinical study for the first Chinese once-monthly GLP-1 RA for weight management.
The study is part of a broader clinical program advancing innovative GLP-1 receptor agonists in China.
This development marks a significant milestone in China's metabolic disease therapeutics, aiming to provide a convenient, long-acting treatment option for obesity and overweight individuals.